


Menin-MLL inhibitor 19

Cat. No.:	HY-139076
CAS No.:	2360487-93-8
Molecular Formula:	C ₃₀ H ₃₄ F ₃ N ₇ O ₄ S
Molecular Weight:	645.7
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 200 mg/mL (309.74 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	1.5487 mL	7.7435 mL	15.4871 mL
				5 mM	0.3097 mL	1.5487 mL	3.0974 mL
				10 mM	0.1549 mL	0.7744 mL	1.5487 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (7.74 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5 mg/mL (7.74 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (7.74 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-ml interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseach of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes ^[1] .
IC ₅₀ & Target	IC ₅₀ : menin-ml interaction ^[1]

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA